Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | TACR3 | P29371 | 8/20 | 0.48 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.44 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.44 |
| ▸ | CTSB | P07858 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5692604 | 1.00 | KDM4E (0.57) | KDM4ESMN1; SMN2ALDH1A1TACR3PLA2G2A | |
| SCHEMBL4981224 | 1.00 | KDM4E (0.57) | KDM4ESMN1; SMN2ALDH1A1TACR3PLA2G2A | |
| SCHEMBL8203094 | 0.93 | KDM4E (0.55) | KDM4ESMN1; SMN2ALDH1A1TACR3PLA2G2A | |
| SCHEMBL8354904 | 0.93 | KDM4E (0.55) | KDM4ESMN1; SMN2ALDH1A1TACR3PLA2G2A | |
| SCHEMBL4617427 | 0.93 | KDM4E (0.55) | KDM4ESMN1; SMN2ALDH1A1TACR3PLA2G2A | |
| SCHEMBL7095755 | 0.89 | KDM4E (0.51) | KDM4ESMN1; SMN2ALDH1A1TACR3PLA2G2A | |
| SCHEMBL4409471 | 0.88 | HTR3E (0.47) | KDM4ESMN1; SMN2ALDH1A1LMNAMAPT | |
| SCHEMBL13451464 | 0.86 | KDM4E (0.48) | KDM4ESMN1; SMN2ALDH1A1TACR3PLA2G2A | |
| SCHEMBL13176984 | 0.86 | KDM4E (0.62) | KDM4ESMN1; SMN2ALDH1A1TACR3PLA2G2A | |
| Hydrochloric Acid SCHEMBL2709962 | 0.86 | DPP4 (0.47) | KDM4ESMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100204159-A1 | ORGANIC COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2010-08-12 | — | — | US | disclosed |
| EP-2066688-A2 | MACROCYCLIC HCV INHIBITORS AND THEIR USES | Novartis AG (CH) | 2009-06-10 | — | — | EP | disclosed |
| WO-2008033389-A2 | MACROCYCLIC HCV INHIBITORS AND THEIR USES | NOVARTIS AG (CH) | 2008-03-20 | — | — | WO | disclosed |
| EP-1337550-B1 | HEPATITIS C TRIPEPTIDE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2006-05-24 | — | — | EP | disclosed |
| US-6872805-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-03-29 | — | — | US | disclosed |
| US-20020111313-A1 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2002-08-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020111313-A1 | Hepatitis C virus inhibitors | HAVCR2, ZC3HAV1, VIP | KDM4E 3925/4885SMN1; SMN2 4835/4885ALDH1A1 3255/4885 |
| US-20100204159-A1 | ORGANIC COMPOUNDS AND THEIR USES | OAT, OTC, AOX1 | KDM4E 4021/4885SMN1; SMN2 877/4885ALDH1A1 135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.